Shares of Sol-Gel Technologies Ltd. (SLGL) have gained nearly 28 percent year-to-date as the company gears up to face the FDA in the coming months.
Sol-Gel is a clinical-stage dermatology company developing branded and generic topical drug products for the treatment of skin diseases. The company has two product candidates under FDA review - one whose decision date falls in April and the other whose decision date is set for August.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com